Tirzepatide Cycle

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown superior weight loss results compared to single-agonist compounds. The SURMOUNT clinical programme demonstrated average weight reductions of 20–22% – significantly more than semaglutide alone. The dual mechanism enhances fat oxidation and metabolic flexibility beyond what GLP-1 activation achieves on its own.

This cycle bundle provides 2 or 3 vials for 8 or 12-week protocols respectively, with proper titration support and significant savings vs single-vial purchases.